BCMA-CAR-T is under clinical development by UTC Therapeutics and currently in Phase I for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase I drugs for Multiple Myeloma (Kahler Disease) have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BCMA-CAR-T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BCMA-CAR-T overview

Gene-modified cell therapy is under development for the treatment of multiple myeloma. The therapy comprises of T-cells genetically engineered to express chimeric antigen receptors (CAR) targeting cells expressing B cell maturation antigen (BCMA).

UTC Therapeutics overview

UTC Therapeutics is a biotechnology company providing T cell based treatments for cancers and other diseases. UTC Therapeutics is headquartered in Shanghai, China.

For a complete picture of BCMA-CAR-T’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.